bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.36 USD
-0.01 (-3.64%)
Updated Nov 14, 2024 04:00 PM ET
2-Buy of 5 2
D Value B Growth C Momentum C VGM
Price, Consensus and EPS Surprise
BLUE 0.36 -0.01(-3.64%)
Will BLUE be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for BLUE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BLUE
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates
Clene Inc. (CLNN) Reports Q3 Loss, Misses Revenue Estimates
BLUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging -22.76% in 4 Weeks, Here's Why the Trend Might Reverse for Bluebird (BLUE)
Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?
Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
Other News for BLUE
Bluebird Bio downgraded to Neutral from Buy at BofA
BofA gets more bearish on Bluebird Bio, downgrades shares
Bluebird Bio price target lowered to $2 from $4 at Barclays
Bluebird Bio price target lowered by $2 at Barclays, here's why
Bluebird Bio downgraded to Underweight from Neutral at JPMorgan